Triera Biosciences · Wholly owned Zentek subsidiary · McMaster University license
Thirty years of
aptamer research.
Now potentially commercially deployable for the first time - custom molecular-recognition tools and rapid diagnostics validated at 100% accuracy.
The platform
An aptamer contract
research organization.
Triera Biosciences is an aptamer contract research organization built on an exclusive 20-year McMaster University license with access to the world's leading aptamer research team. In tandem with McMaster, Triera delivers custom molecular-recognition tools for pharma and biotech, and rapid diagnostics validated at 100% machine-learning classification accuracy in a published study involving 172 patient samples.
Aptamer
\ ˈap-tə-mər \
A short, synthetic strand of DNA or RNA that folds into a precise three-dimensional shape, allowing it to bind with extraordinary selectivity to a specific target - a protein, a pathogen, a toxin, a cancer biomarker. Think of it as a molecular key cut precisely for one lock.
01 · Aptamer vs antibody
Synthetic, stable, adaptable.
Antibodies are biological - grown in animals or cell cultures, expensive to manufacture, and slow to adapt to new variants. Aptamers are synthetic: made by chemical synthesis, stable at room temperature, cheaper to produce at scale, and optimizable to bind a new target in weeks.
Triera's trimeric and multivalent aptamer families exploit expanded architecture - multiple binding arms on a single molecule locking onto a target from several angles at once - to achieve binding strength and specificity no single-site antibody can match.
02 · Why now
The timing inflection.
The fundamental science has been published for thirty years across 21,000+ papers. The barrier was never the biology - it was the full-stack capability to go from aptamer discovery through sensor engineering, machine learning-based signal classification, and clinical validation within a single team.
Triera has assembled that capability. The 100% machine learning accuracy result, published in a peer-reviewed journal on real patient samples, is the proof-of-concept the market has been waiting for.
See validated targetsMarket opportunity
A fast-growing market,
a full-stack team.
The global aptamers market is one of the fastest-growing segments in biotech tools and reagents. The figures below reflect market opportunity only, not projected revenue.
CRO services
Three service lines.
One compounding IP portfolio.
Triera operates the same model as Zentek's coatings platform: client-funded development work, IP retained by Triera. Three distinct service lines, each addressable in the near term, each compounding the same patent portfolio.
Custom aptamer discovery
Pharma and biotech pay $50K–$500K per project for custom aptamer development. Triera's team executes the full stack - target identification, SELEX discovery, sensor engineering, machine learning classification, and validation. Triera retains commercial rights; the client receives a use licence.
Start an engagementRapid diagnostic products
Five validated targets in the pipeline, each built on the same aptamer-sensor-machine learning platform - validated at 100% classification accuracy on 172 real patient samples (ACS Sensors, January 2025). Each additional target adds a product, not a platform rebuild.
View pipelineGovernment programmes
Government pandemic-preparedness programs fund aptamer-based countermeasure development. Triera's validated platform and peer-reviewed clinical results position it as a preferred domestic partner. Active relationships include Defence Research and Development Canada (DRDC) for defence diagnostics applications.
Diagnostic pipeline
Five validated targets.
One reusable platform.
Each diagnostic target is built on the same aptamer-sensor-machine learning platform validated in the January 2025 ACS Sensors publication. Adding a new target is an engineering program - not a platform rebuild.
Influenza A
Respiratory pathogen causing seasonal epidemics and periodic pandemics. Existing rapid tests are antibody-based with limited sensitivity to novel strains; an aptamer platform adapts to new variants in weeks versus months of antibody re-validation.
Syphilis
Treponema pallidum. Incidence has risen sharply across North America and Europe since 2015. Existing tests require lab processing; a stable, room-temperature aptamer rapid test is viable where antibody-based equivalents are not.
COVID-19
SARS-CoV-2. Now an endemic respiratory illness but a substantial market. The platform's adaptability to new variants - redesign in weeks, not years - is a structural advantage over antibody tests requiring lengthy re-validation as dominant variants shift.
Norovirus
The leading cause of acute gastroenteritis worldwide, infecting an estimated 685 million people annually. Existing diagnostics are predominantly lab-based; a room-temperature-stable aptamer rapid test enables detection in healthcare facilities, schools, cruise ships and other high-risk settings.
VEGF · cancer
Vascular Endothelial Growth Factor, a key biomarker for tumour angiogenesis. Elevated levels correlate with progression and therapeutic response across cancer types; an aptamer detection platform could provide a rapid, low-cost liquid-biopsy monitoring tool.
The common architecture
All five targets share the same electrochemical sensor platform and machine learning classification engine. The machine learning model achieved 100% diagnostic accuracy on 172 real patient samples - clinical specimens, not laboratory controls. Each new target requires aptamer selection and sensor optimisation, not a new platform.
The commercialisation barrier was never the science - it was the absence of a team with full-stack capability. That team now exists.Triera Biosciences · Aptamer platform
The research team
The world's leading
aptamer research team.
Triera's three McMaster University lead researchers collectively built the science the field now cites, with 588 combined publications. Their full-stack expertise spans aptamer discovery, electrochemical sensor engineering, machine learning-based signal classification, and clinical validation.
Exclusive McMaster license
An exclusive 20-year license to McMaster University's aptamer technology anchors Triera's IP portfolio and gives it commercial rights to a body of work three decades in the making.
588 publications
McMaster and Zentek combined publications - a depth of peer-reviewed science that underwrites the platform's credibility with pharma, biotech, and government partners.
100% Machine learning accuracy
Published in ACS Sensors, January 2025: 100% diagnostic classification accuracy on 172 real patient samples, using the reusable aptamer-sensor-machine learning platform.
CRO engagement
Start a custom
discovery engagement.
Pharmaceutical, biotech, diagnostics manufacturers, and government agencies engage Triera for custom aptamer development. Engagements run from $50,000 to $500,000 per project, on timelines of weeks to months rather than years. Triera retains commercial IP rights; the client receives a use licence to the developed aptamer.
$50K – $500K
Per project, scoped to the target and validation depth required.
Weeks to months
Per engagement - a fraction of the antibody development cycle.
Pharma & government
Pharma, biotech, diagnostics manufacturers, and government agencies.